| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 401.67% | HC Wainwright & Co. | $50 → $15 | Maintains | Buy |
| 08/11/2023 | 401.67% | B. Riley Securities | $20 → $15 | Maintains | Buy |
| 07/12/2023 | 401.67% | JMP Securities | → $15 | Reiterates | Market Outperform → Market Outperform |
| 05/15/2023 | 1572.24% | HC Wainwright & Co. | → $50 | Reiterates | Buy → Buy |
| 05/11/2023 | 401.67% | JMP Securities | $15 → $15 | Reinstates | Market Outperform → Market Outperform |
| 03/31/2023 | 401.67% | JMP Securities | → $15 | Reiterates | → Market Outperform |
| 03/22/2023 | 769.57% | JMP Securities | → $26 | Reiterates | → Market Outperform |
| 03/22/2023 | 100.67% | Goldman Sachs | $20 → $6 | Downgrades | Buy → Neutral |
| 03/09/2023 | 1572.24% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/06/2023 | 769.57% | JMP Securities | → $26 | Reiterates | → Market Outperform |
| 01/20/2023 | 1572.24% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 01/18/2023 | 736.12% | Evercore ISI Group | $14 → $25 | Maintains | Outperform |
| 12/01/2022 | 568.9% | Goldman Sachs | → $20 | Initiates Coverage On | → Buy |
| 11/11/2022 | 769.57% | JMP Securities | $28 → $26 | Maintains | Market Outperform |
| 09/16/2022 | 769.57% | Guggenheim | $31 → $26 | Maintains | Buy |
| 08/31/2022 | 1070.57% | Jefferies | $30 → $35 | Maintains | Buy |
| 08/17/2022 | 1572.24% | HC Wainwright & Co. | $25 → $50 | Maintains | Buy |
| 08/12/2022 | 769.57% | B. Riley Securities | $21 → $26 | Maintains | Buy |
| 05/18/2022 | 736.12% | Piper Sandler | $34 → $25 | Maintains | Overweight |
| 06/30/2021 | 602.34% | B. Riley Securities | $41 → $21 | Maintains | Buy |
| 06/30/2021 | 936.79% | JMP Securities | $53 → $31 | Maintains | Market Outperform |
| 06/30/2021 | 736.12% | HC Wainwright & Co. | $35 → $25 | Maintains | Buy |
| 06/16/2021 | 1672.58% | JMP Securities | $45 → $53 | Maintains | Market Outperform |
| 06/02/2021 | 1070.57% | HC Wainwright & Co. | → $35 | Initiates Coverage On | → Buy |
| 02/11/2021 | 1104.01% | Guggenheim | → $36 | Initiates Coverage On | → Buy |
| 11/24/2020 | 736.12% | Evercore ISI Group | → $25 | Reinstates | → Outperform |
| 09/25/2020 | 936.79% | B. Riley Securities | → $31 | Initiates Coverage On | → Buy |
| 07/31/2020 | 2575.59% | Piper Sandler | → $80 | Initiates Coverage On | → Overweight |
| 07/28/2020 | 1572.24% | JMP Securities | → $50 | Initiates Coverage On | → Market Outperform |
| 07/19/2019 | 177.59% | Roth Capital | → $8.3 | Initiates Coverage On | → Buy |
What is the target price for Altimmune (ALT)?
The latest price target for Altimmune (NASDAQ: ALT) was reported by HC Wainwright & Co. on August 14, 2023. The analyst firm set a price target for $15.00 expecting ALT to rise to within 12 months (a possible 401.67% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Altimmune (ALT)?
The latest analyst rating for Altimmune (NASDAQ: ALT) was provided by HC Wainwright & Co., and Altimmune maintained their buy rating.
When is the next analyst rating going to be posted or updated for Altimmune (ALT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Altimmune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Altimmune was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
Is the Analyst Rating Altimmune (ALT) correct?
While ratings are subjective and will change, the latest Altimmune (ALT) rating was a maintained with a price target of $50.00 to $15.00. The current price Altimmune (ALT) is trading at is $2.99, which is out of the analyst's predicted range.